75893-82-2

Basic information

• Product Name: 6-FLUORO-3,4-DIHYDROQUINOLIN-2(1H)-ONE
• Synonyms: 6-FLUORO-3,4-DIHYDROQUINOLIN-2(1H)-ONE;6-FLUORO-3,4-DIHYDRO-1H-QUINOLIN-2-ONE;6-fluoro-3,4-dihydro-2(1H)-quinolinone(SALTDATA: FREE);6-fluoro-1,2,3,4-tetrahydroquinolin-2-one;6-fluoro-3,4-dihydrocarbostyril;3,4-Dihydro-6-fluoro-2(1H)-quinolinone;6-Fluoro-2-oxo-1,2,3,4-tetrahydroquinoline;6-fluoro-3,4-dihydro-2(1H)-quinolinone
• CAS NO: 75893-82-2
• Molecular Formula: C₉H₈FNO
• Molecular Weight: 165.17
• EINECS: 604-604-1
• Mol File: 75893-82-2.mol

Chemical Properties

• Boiling Point: 323.5 °C at 760 mmHg
• Flash Point: 149.5 °C
• Appearance: /
• Density: 1.241 g/cm³
• CAS DataBase Reference: 6-FLUORO-3,4-DIHYDROQUINOLIN-2(1H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-FLUORO-3,4-DIHYDROQUINOLIN-2(1H)-ONE(75893-82-2)
• EPA Substance Registry System: 6-FLUORO-3,4-DIHYDROQUINOLIN-2(1H)-ONE(75893-82-2)

Safety Data

• Hazardous Substances Data: 75893-82-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-FLUORO-3,4-DIHYDROQUINOLIN-2(1H)-ONE is used as a building block for the synthesis of various drugs and biologically active compounds due to its unique structure and fluorine substitution, which can enhance the therapeutic properties of the resulting pharmaceuticals.
Used in Antimicrobial Applications:
6-FLUORO-3,4-DIHYDROQUINOLIN-2(1H)-ONE is used as an antimicrobial agent for its demonstrated properties against certain microorganisms, making it a potentially valuable component in the development of new antimicrobial agents to combat resistant strains.
Used in Antifungal Applications:
6-FLUORO-3,4-DIHYDROQUINOLIN-2(1H)-ONE is used as an antifungal agent, leveraging its ability to inhibit the growth of fungi, which is crucial in the development of treatments for fungal infections.

Upstream product

• 771-19-7 1-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline 
• 61272-76-2 4-fluoro-2-iodoaniline 
• 140-88-5 ethyl acrylate 
• 371-40-4 4-fluoroaniline 
• 56767-37-4 3-chloro-N-(4-fluorophenyl)propionamide 
• 459-31-4 3-(4-fluorophenyl)propanoic acid 
• 772-70-3 3-(4-fluorophenyl)propanoyl chloride 
• 635-46-1 1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 59611-52-8 6-fluoro-1,2,3,4-tetrahydroquinoline 
• 1610667-34-9 1-benzyl-6-fluoro-3.4-dihydroquinolin-2(1H)-one 
• 22614-75-1 6-fluoro-1H-quinolin-2-one 
• 792122-31-7 6-fluoro-3-(3-methylamino-propyl)-1-p-tolyl-3,4-dihydro-1H-quinolin-2-one 

Relevant articles and documents

Ruthenium-catalyzed intramolecular arene C(sp2)-H amidation for synthesis of 3,4-dihydroquinolin-2(1 H)-ones

We report the [Ru(p-cymene)(l-proline)Cl] ([Ru1])-catalyzed cyclization of 1,4,2-dioxazol-5-ones to form dihydroquinoline-2-ones in excellent yields with excellent regioselectivity via a formal intramolecular arene C(sp2)-H amidation. The reactions of the 2- and 4-substituted aryl dioxazolones proceeds initially through spirolactamization via electrophilic amidation at the arene site, which is para or ortho to the substituent. A Hammett correlation study showed that the spirolactamization is likely to occur by electrophilic nitrenoid attack at the arene, which is characterized by a negative ρ value of -0.73.

Compound for inhibiting EGFR kinase as well as preparation method and application thereof

The invention provides a compound as shown in a general formula (I) and pharmaceutically acceptable salt thereof as well as a preparation method and application of the compound. The compound can selectively inhibit the activity of an EGFR (epidermal growt

Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model

Histone deacetylase 6 (HDAC6) is a promising therapeutic target for the treatment of neurodegenerative disorders. SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and sel

TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS

Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, tr

Regiodivergent access to five- and six-membered benzo-fused lactams: Ru-catalyzed olefin hydrocarbamoylation

We report herein a new strategy of the Ru-catalyzed intramolecular olefin hydrocarbamoylation for the regiodivergent synthesis of five- and six-membered benzo-fused lactams starting from N-(2-alkenylphenyl)formamides. Using a combined catalyst of Ru3

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease, such as malaria, caused by a Plasmodium parasite.

Novel approach to 3,4-dihydro-2(1H)-quinolinone derivatives via cyclopropane ring expansion

N-(1'-Alkoxy)cyclopropyl-2-haloanilines are transformed to 3,4-dihydro-2(1H)-quinolinones via palladium-catalyzed cyclopropane ring expansion. The reaction tolerates a variety of functional groups such as ester, nitrile, ether, and ketone group

NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS

The present invention relates to novel M1 agonistic compounds of formula (I) and their use in the treatment of cognitive impairment associated i.a. with schizophrenia and in the treatment of other diseases mediated by the muscarinic M1 receptor.

The tandem reaction combining radical and ionic processes: an efficient approach to substituted 3,4-dihydroquinolin-2-ones

3,4-Dihydroquinolin-2-ones are of great importance in the areas of pharmaceuticals. However, the direct intramolecular radical cyclizations of the corresponding amide compounds favor 5-exo products 2. Reports on the radical cyclization reactions producing

TETRAHYDROQUINOLINE, INDOLINE, AND RELATED ANILINE DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES

The present invention relates to a compound of the formula: or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, useful as modulators of 5 -HTi A receptor activity and/or serotonin reuptake. These compounds are useful in treating nervous system disorders, such as anxiety-related disorders, cognition-related disorders, depression, schizophrenia, or sexual dysfunction and related illnesses.